Skip to main content

Advertisement

SpringerLink
Log in

New therapeutical horizons in the management of postmenopausal osteoporosis

  • Short Communication
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Osteoporosis is a bone metabolic disease characterized by a compromised skeletal fragility, leading to an increased risk of developing spontaneous and traumatic fractures. This disease is the consequence of an imbalance of the physiological process of bone turnover (or coupling), with the lost of the equilibrium between the activity of osteoblasts and osteoclasts. Therapy has been aimed mainly at the correction of the imbalance between bone resorption and bone formation, to protect skeletal integrity and reduce the risk of fractures. Thus, pharmacological treatments have been aimed at modulating the activity of bone cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gold DT (2001) The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. Rheum Dis Clin North Am 27:255–262

    Article  PubMed  CAS  Google Scholar 

  2. Migliaccio S, Brama M, Spera G (2007) The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis. Clin Interv Aging 2(1):55–64

    Article  PubMed  CAS  Google Scholar 

  3. Migliaccio S, Falcone S, Spera G (2004) Bone modelling and remodelling: from biology to clinical application. Aging Clin Exp Res 3:S20–S22

    Google Scholar 

  4. Seeman E (2003) Bone quality. Osteoporos Int 14(S5):3–7

    Article  Google Scholar 

  5. Adami S, Bertoldo F, Brandi ML, SIOMMMS et al (2009) Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61(4):260–284

    PubMed  CAS  Google Scholar 

  6. Diez-Perez A (2002) Bisphosphonates. Maturitas 43(Suppl):S19–S26

    Article  PubMed  CAS  Google Scholar 

  7. Taranta A, Brama M et al (2002) The selective estrogen receptor modulator Raloxifene modulates osteoblast and osteoclast activity in vitro. Bone 30:365–376

    Article  Google Scholar 

  8. Ettinger B, Black DM et al (1999) Reduction of vertebral fracture risk in post menopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282:637–645

    Article  PubMed  CAS  Google Scholar 

  9. Blick SD, Dhillon S, Keam SJ (2008) Teriparatide: a review of its use in osteoporosis. Drugs 68:2709–2737

    Article  PubMed  CAS  Google Scholar 

  10. Neer RM, Arnaud CD et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  PubMed  CAS  Google Scholar 

  11. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916

    Article  PubMed  CAS  Google Scholar 

  12. Cosman F (2008) Parathyroid hormone treatment for osteoporosis. Curr Opin Endocrinol Diabetes Obes 15:495–501

    Article  PubMed  CAS  Google Scholar 

  13. Wang BL, Dai CL et al (2006) Parathyroid hormone regulates osterix and Runx2 mRNA expression predominantly through protein kinase A signalling in osteoblast-like cells. J Endocrinol Investig 29:101–108

    CAS  Google Scholar 

  14. Gesty-Palmer D, Chen M et al (2006) Distinct beta-arrestin and G-protein-dependent pathways for parathyroid hormone receptor-stimulated ERK ½ activation. J Biol Chem 281:10856–10864

    Article  PubMed  CAS  Google Scholar 

  15. Sabatini M, Lesur C et al (1996) Effects of parathyroid hormone and agonists of the adenylyl cyclase and protein kinase C pathways on bone cell proliferation. Bone 18:59–65

    Article  PubMed  CAS  Google Scholar 

  16. Virk MS, Alaee F et al (2013) Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am 95(8):694–701

    Article  PubMed  Google Scholar 

  17. Yasuda H, Shima N et al (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602

    Article  PubMed  CAS  Google Scholar 

  18. Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613–635

    Article  PubMed  CAS  Google Scholar 

  19. Burgess TL, Quian Y et al (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527–538

    Article  PubMed  CAS  Google Scholar 

  20. Brixen K, Chapurlat R et al (2013) Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. JCEM 98(2):571–580

    PubMed  CAS  Google Scholar 

  21. Langdahl B, Binkley N et al (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. JBMR 27:2251–2258

    Article  CAS  Google Scholar 

  22. Pereira RG, Delany AM, Canalis E (2002) Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 30:685–691

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

No conflict of interest exists for all authors.

Author information

Authors and Affiliations

  1. Endocrinology Unit, Department of Movement, Human and Health Sciences, University of “Foro Italico”, Largo de Bosis 14, 00135, Rome, Italy

    Silvia Migliaccio & Luigi Di Luigi

  2. Department of Experimental Medicine, Section of Medical Pathophysiology, Endocrinology and Nutrition, University “Sapienza” of Rome, Rome, Italy

    Rachele Fornari, Emanuela A. Greco & Andrea Lenzi

Authors
  1. Silvia Migliaccio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachele Fornari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emanuela A. Greco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luigi Di Luigi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrea Lenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvia Migliaccio.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Migliaccio, S., Fornari, R., Greco, E.A. et al. New therapeutical horizons in the management of postmenopausal osteoporosis. Aging Clin Exp Res 25 (Suppl 1), 117–119 (2013). https://doi.org/10.1007/s40520-013-0106-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40520-013-0106-x

Keywords

Search

Navigation